TY - JOUR
T1 - Clinical characteristics and outcome of familial nonmedullary thyroid cancer
T2 - A retrospective controlled study
AU - Robenshtok, Eyal
AU - Tzvetov, Gloria
AU - Grozinsky-Glasberg, Simona
AU - Shraga-Slutzky, Ilana
AU - Weinstein, Ruth
AU - Lazar, Liora
AU - Serov, Svetlana
AU - Singer, Joelle
AU - Hirsch, Dania
AU - Shimon, Ilan
AU - Benbassat, Carlos
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Background: Familial nonmedullary thyroid cancer (FNMTC) is a disease defined by clustering of thyroid cancers of follicular cell origin, and it is estimated to account for 5% of all thyroid cancers. Several studies found FNMTC to be more aggressive than sporadic disease, whereas others found them to have a similar course and outcome. The purpose of this study was to determine whether FNMTC is more aggressive than sporadic thyroid cancer. Methods: A retrospective controlled study of FNMTC versus sporadic nonmedullary thyroid cancers was conducted using a registry of patients with thyroid cancer. Data on disease severity at presentation, treatment modalities, and outcome were collected. Results: Sixty-seven patients with FNMTC and 375 controls with sporadic disease were included. Follow-up period was 8.6 ± 10 years for patients with FNMTC and 8.4 ± 9.1 years for sporadic cases. Patients with FNMTC had comparable disease severity at diagnosis as sporadic patients, underwent similar surgical and radioiodine treatments, and had similar long-term disease-free survival. Long-term outcome in families with three or more affected relatives was similar to families with only two affected relatives. Conclusions: Our results suggest that FNMTC is not more aggressive than sporadic thyroid cancer within our studied population. After a similar therapeutic strategy, FNMTC and sporadic cases had comparable prognosis, including in families with three or more affected members.
AB - Background: Familial nonmedullary thyroid cancer (FNMTC) is a disease defined by clustering of thyroid cancers of follicular cell origin, and it is estimated to account for 5% of all thyroid cancers. Several studies found FNMTC to be more aggressive than sporadic disease, whereas others found them to have a similar course and outcome. The purpose of this study was to determine whether FNMTC is more aggressive than sporadic thyroid cancer. Methods: A retrospective controlled study of FNMTC versus sporadic nonmedullary thyroid cancers was conducted using a registry of patients with thyroid cancer. Data on disease severity at presentation, treatment modalities, and outcome were collected. Results: Sixty-seven patients with FNMTC and 375 controls with sporadic disease were included. Follow-up period was 8.6 ± 10 years for patients with FNMTC and 8.4 ± 9.1 years for sporadic cases. Patients with FNMTC had comparable disease severity at diagnosis as sporadic patients, underwent similar surgical and radioiodine treatments, and had similar long-term disease-free survival. Long-term outcome in families with three or more affected relatives was similar to families with only two affected relatives. Conclusions: Our results suggest that FNMTC is not more aggressive than sporadic thyroid cancer within our studied population. After a similar therapeutic strategy, FNMTC and sporadic cases had comparable prognosis, including in families with three or more affected members.
UR - http://www.scopus.com/inward/record.url?scp=78651284482&partnerID=8YFLogxK
U2 - 10.1089/thy.2009.0406
DO - 10.1089/thy.2009.0406
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 20954815
AN - SCOPUS:78651284482
VL - 21
SP - 43
EP - 48
JO - Thyroid
JF - Thyroid
SN - 1050-7256
IS - 1
ER -
